Prime Highlights
- Deepak Sapra will become Gland Pharma’s CEO in November, bringing more than 23 years of pharma experience.
- Gland Pharma’s Q1 FY27 net profit jumped 47.1% to ₹317 crore, while revenue rose 19.6%.
Key Facts
- Gland Pharma is a Hyderabad-based pharmaceutical company focused on injectable medicines and related products.
- Shares have gained more than 67% in six months and recently touched a fresh 52-week high of ₹3,025.
Background
Gland Pharma shares gained nearly 2% on Friday after the company announced a leadership change, with Deepak Sapra set to become its next Chief Executive Officer (CEO). The stock also touched a fresh 52-week high of ₹3,025 during the session.
Sapra currently serves as CEO – API and Services at Dr Reddy’s Laboratories and sits on the board of Aurigene Pharma Services. In his current role, he oversees business growth across key markets, including the US, Europe, Japan, Brazil, China, Mexico and the Middle East. He brings more than 23 years of experience in the pharmaceutical industry.
Sapra will take charge as Gland Pharma’s CEO in November, succeeding Shyamakant Giri, who stepped down from the position in April. The appointment comes as the Hyderabad-based drugmaker reports strong financial growth and a sharp rise in its stock price.
Gland Pharma posted a 47.1% year-on-year increase in net profit to ₹317 crore in the first quarter of FY27, compared with ₹215 crore a year earlier. Revenue increased from ₹1,505.6 crore to ₹1,800.2 crore, a 19.6% increase.
The company also reported a 33.1% rise in EBITDA to ₹489.2 crore, while its EBITDA margin improved to 27.2% from 24.4%. Adjusted EBITDA margin stood at 28%.
The stock has gained more than 67% over the past six months and has risen in seven of the last 10 trading sessions. Friday marked its second consecutive session of gains, highlighting strong investor interest following the leadership announcement and robust quarterly performance. The company’s improving earnings and leadership transition could keep investor focus on its growth plans and business expansion.